Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : GlaxoSmithKline Research & Development Limited
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Limited
MAJ Il y a 5 ans
A Study to Evaluate the Safety and how Effective a Medicine is at one of two doses to Treat COPD
The primary objective is to compare the efficacy and evaluate safety of GSK573719 Inhalation Powder (62.5 mcg and 125 mcg) with placebo when administered once-daily via a Novel Dry Powder Inhaler over...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Limited
MAJ Il y a 5 ans
A Randomized, Double Blind, Parallel Group, Placebo Controlled 28 Day Study to Investigate the Safety, Tolerability and Pharmacodynamics of SB-656933 in Patients with Cystic Fibrosis
To assess the safety and tolerability of 28 days repeat dosing with SB-656933 in subjects with cystic fibrosis
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Limited
MAJ Il y a 5 ans
A study to investigate belimumab for the treatment of chronic immune thrombocytopenia
The Primary Objective : To evaluate whether belimumab can demonstrate a clinical response in ITP, using a surrogate clinical measure of platelet count, to clarify mechanism ofaction of belimumab.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Limited
MAJ Il y a 5 ans
Umeclidinium bromide added onto fluticasone furoate/ vilanterol in COPD - Study 2
The primary objective is to evaluate the efficacy and safety of the addition of UMEC 125 mcg to FF/VI 100/25 mcg once-daily and the addition of UMEC 62.5 mcg to FF/VI 100/25 mcg once-daily, compared w...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Limited
MAJ Il y a 5 ans
The efficacy of orally administered GSK2190915 as an add-on to current therapy in subjects with moderate to severe asthma who have elevated sputum neutrophils
To evaluate the effect of treatment with repeat oral doses of GSK2190915 on the number of neutrophils in induced sputum in moderate to severe asthmatic subjects compared with placebo
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
GlaxoSmithKline Research & Development Limited
MAJ Il y a 4 ans
A Phase II, Open-Label, Randomized, Multicenter Trial of GW786034 (Pazopanib) in Combination with Lapatinib (GW572016) Compared to Lapatinib Alone as First Line Therapy in Subjects with Advanced or Metastatic Breast Cancer with ErbB2 Fluorescence In Situ Hybridization (FISH) Positive Tumors
To compare the rate of disease progression at 12 weeks between pazopanib in combination with lapatinib versus lapatinib alone in subjects with locally advanced or metastatic breast cancer whose tumors...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
GlaxoSmithKline Research & Development Limited
MAJ Il y a 5 ans
A multi-centre, randomised, double-blind, placebo-controlled, four-way incomplete crossover study to examine efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of single and repeat administration of three inhaled doses (10, 15, and 20mcg) of GSK159797
•To determine the trough (mean of 23 and 24 hour) FEV1 after 14 day repeat doses of inhaled GSK159797 (10, 15, and 20mcg) administered once daily in persistent asthmatic subjects.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Limited
MAJ Il y a 5 ans
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg administered orally once daily, in Adults with Rheumatoid Arthritis
• To evaluate the clinical efficacy of GW406381versus placebo in the treatment of the signs and symptoms of Rheumatoid Arthirtis.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Limited
MAJ Il y a 5 ans
A multicentre, randomised, double-blind, placebo-controlled, dose ascending, four way crossover study to examine efficacy (FEV1),safety, tolerability, pharmacodynamics and pharmacokinetics of single and repeat doses of GW642444
To determine the 24hour FEV1 after a single dose of GW642444 in mild to moderate asthmatic subjects.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Limited
MAJ Il y a 5 ans
A two-centre, randomised, double-blind, placebo-controlled, 2-period cross-over study to evaluate the effect of treatment with repeat doses of inhaled GSK256066 on the allergen-induced late asthmatic response in subjects with mild asthma
To evaluate the effect of treatment with repeat inhaled doses of GSK256066 for 14 days on the late asthmatic response (LAR) to inhaled allergen in mild asthmatic subjects compared with placebo
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4
5
6
7
8
9
10
Suivant